Gilead Sciences (NQ:GILD)

Gilead Sciences cleanly beat fourth-quarter expectations late Tuesday, but Gilead stock could take a hit on its light outlook.

Topics Earnings

Will Gilead's Solid Fourth Quarter Be Enough To Shake Off Its Light Outlook? ↗

February 10, 2026

Via Investor's Business Daily

Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

February 10, 2026

GILEAD SCIENCES INC (NASDAQ:GILD): A High-Yield, Low-Payout Dividend Stock for Disciplined Investors ↗

Gilead Sciences Inc. (NASDAQ:GILD) Passes the Caviar Cruise Quality Investing Screen ↗

January 22, 2026

Via Chartmill

January 20, 2026

Via Chartmill

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

February 10, 2026

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the...

Via Finterra

Topics Economy Intellectual Property

Should You Buy Gilead Sciences Before Feb. 10? ↗

February 09, 2026

Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue?

Via The Motley Fool

Exploring Gilead Sciences's Earnings Expectations ↗

February 09, 2026

Via Benzinga

Gilead Sciences (GILD) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 08, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday afternoon. Here’s what you need to know.

FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma

Topics Artificial Intelligence World Trade

February 06, 2026

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 5 Years ↗

February 05, 2026

Via Benzinga

This Overlooked Biotech Giant Could Surprise Investors This Quarter

February 05, 2026

Investors may be underestimating the long-term potential of Gilead’s evolving portfolio.

Via Barchart.com

1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Challenges

February 02, 2026

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Crossroads4Hope Kicks Off Its 25th Year of Caring with the Launch of Free Breast and Colorectal Cancer Resources for Patients and Families Nationwide

February 02, 2026

Via PRLog

Large Cap Biopharmaceuticals: A Core Position For A Healthcare Portfolio ↗

February 02, 2026

Large-cap biopharma offers stable growth and dividends, outperforming the S&P 500 in early 2026. With Gilead up 46% and Pfizer yielding 6%, the sector remains a key volatility hedge following...

Via Talk Markets

Topics Stocks

3 Cash-Producing Stocks with Warning Signs

January 29, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

The Commonwealth Club Honors Black History Month With Event Featuring Top Black Leaders in AI & Biopharma Discussing the Future of Healthcare

January 29, 2026

Via Get News

Topics Artificial Intelligence

Are Wall Street Analysts Predicting Gilead Sciences Stock Will Climb or Sink?

January 29, 2026

Gilead Sciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

Via Barchart.com

Topics ETFs

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

January 27, 2026

Here's How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today ↗

Demystifying Gilead Sciences: Insights From 17 Analyst Reviews ↗

January 27, 2026

Via Benzinga

Exploring the top movers within the S&P500 index during today's session. ↗

January 23, 2026

Via Chartmill

January 22, 2026

Via Benzinga

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

January 21, 2026

Gilead Sciences is expected to release its fiscal fourth-quarter earnings soon, and analysts project a decline in EPS.

Gilead Sciences Earnings Preview: What to Expect

January 19, 2026

Via Barchart.com

Topics Artificial Intelligence ETFs Government

Looking Into Gilead Sciences Inc's Recent Short Interest ↗

January 16, 2026

Via Benzinga

A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM)

January 13, 2026

Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage...

Via PredictStreet

Topics Economy Initial Public Offering

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

Topics Government

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings?

January 05, 2026

Gilead Sciences trades at $117.95 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 10.1%.